MINI FUTURE LONG - UNITED THERAPEUTICS Share Price

Certificat

DE000ME9DJ82

Market Closed - Bid/Ask 12:14:43 07/06/2024 am IST After market 12:59:57 am
7.21 EUR -2.70% Intraday chart for MINI FUTURE LONG - UNITED THERAPEUTICS 7.28 +0.97%
Current month+3.64%
1 month+20.88%
Date Price Change
07/24/07 7.21 -2.70%
05/24/05 7.41 +6.93%
04/24/04 6.93 -5.20%
03/24/03 7.31 +2.24%
31/24/31 7.15 +5.30%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 12:14 am IST

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellCALL
Underlying UNITED THERAPEUTICS CORPORATION
Issuer Morgan Stanley
WKN ME9DJ8
ISINDE000ME9DJ82
Date issued 28/02/2024
Strike 197.9 $
Maturity Unlimited
Parity 10 : 1
Emission price 2.85
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 7.47
Lowest since issue 2.89
Spread 0.08
Spread %1.09%

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Sector
-
More about the company

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: United Therapeutics Corporation

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
276.7 USD
Average target price
294.2 USD
Spread / Average Target
+6.30%
Consensus